Novel Strategies Can Help Manage N2 Disease in NSCLC Patients

Immunotherapy using new PD-1 receptors and other markers may help prevent a systemic reoccurrence of N2 disease in patients with non-small cell lung cancer (NSCLC), according to Robert J. Cerfolio, MD, MBA, from NYU Langone’s Perlmutter Cancer Center.

STS/CATS/CSCS: Difficult Decisions in Thoracic Surgery—Advice From Canadian and American Experts

Monday, January 29
11:30 a.m. – 12:30 p.m.
Room 305

“This represents a paradigm shift for us as surgeons in the very diverse group of patients with N2 disease, which is controversial because we are now seeing patients who are 2 and 3 years out of chemotherapy for stage IIA N2 disease and only have local disease left that can be resected with lobectomy,” said Dr. Cerfolio. “Immunotherapy has changed our landscape a bit in these patients and may make the North American surgeon as aggressive as the European surgeon for N2 disease upfront, as the need for improved local therapy may increase, and the role of surgery may be revisited as the direct line of treatment.”

Difficult decisions regarding the treatment of N2 disease will be discussed today during a collaborative, case-based session organized by STS, the Canadian Association of Thoracic Surgeons, and the Canadian Society of Cardiac Surgeons.

“N2 disease must be identified prior to the start of thoracic oncologic therapy or procedures, as we increasingly focus on safe therapeutic treatment strategies,” Dr. Cerfolio said, adding that North American surgeons still prefer that patients with biopsy-proven N2 disease undergo neoadjuvant therapy prior to surgery.

In addition to the management of N2 disease in the NSCLC patient, session participants will discuss various approaches to managing airway injuries and fistulae following esophagectomy.